Latest Idexx Laboratories (IDXX) Headlines Idex
Post# of 36
Posted On: 03/12/2014 10:21:03 PM
Latest Idexx Laboratories (IDXX) Headlines
Idexx Laboratories Shares Up 20.2% Since SmarTrend's Buy Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Mar 12, 11:07AM CDT
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 3 months, Idexx Laboratories has returned 20.18% as of today's recent price of $127.85.
IDEXX Laboratories names Daniel Junius as member of the board
M2 - Wed Mar 12, 7:59AM CDT
Diagnostics and information technology solutions for animal health care company IDEXX Laboratories (NASDAQ:IDXX) announced on Tuesday that Daniel M Junius has been elected as a member of the company's board of directors, with immediate effect.
IDEXX Laboratories Elects Daniel Junius to Board of Directors
PR Newswire - Tue Mar 11, 3:15PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced the unanimous election of Daniel M. Junius as a member of the Company's Board of Directors, effective March 11, 2014. Mr. Junius fills a vacancy on the Board for a Class I director, the remaining term for which ends at the Company's 2015 annual meeting of stockholders.
Idexx Laboratories Has Returned 18.4% Since SmarTrend Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Mar 05, 9:46AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 2 months, Idexx Laboratories has returned 18.42% as of today's recent price of $125.98.
Idexx Laboratories Shares Up 18.4% Since SmarTrend's Buy Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Feb 26, 9:20AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 2 months, Idexx Laboratories has returned 18.44% as of today's recent price of $126.00.
IDEXX Laboratories to Present at Raymond James 35th Annual Institutional Investors Conference
PR Newswire - Tue Feb 25, 3:38PM CST
IDEXX Laboratories, Inc. (NASDAQ: IDXX), announced today that it will participate in the Raymond James 35th Annual Institutional Investors Conference. Brian McKeon, Executive Vice President and Chief Financial Officer, is scheduled to make a presentation on the Company on Tuesday, March 4, 2014 at 11:35 a.m. ET, at the JW Marriott Grande Lakes, Orlando, Florida. Individuals can access the live audio webcast of the presentation through a link on the home page of the IDEXX Laboratories website, www.idexx.com. An archived edition of the presentation will be available for 14 days via the same link.
Insider Trading Alert - IDXX, AGN And BGC Traded By Insiders
at The Street - Tue Feb 25, 9:02AM CST
Stocks with insider trader activity include IDXX, AGN and BGC
Shares of IDXX Up 18.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 18, 4:53PM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.38. In approximately 2 months, Idexx Laboratories has returned 18.06% as of today's recent price of $125.60.
This Company's "Dismal" Performance Masks Excellent Opportunity
John Leonard, The Motley Fool - Motley Fool - Fri Feb 14, 1:30PM CST
Abaxis fell sharply after reporting disappointing results last month. However the recent recovery suggests the market is beginning to realize that the cause for the "dismal" results (the CEO's words) is most likely a one-off occurrence rather...
Navios Maritime Holdings to Ring the NYSE Closing Bell(R), Commemorating the Company's 60th Anniversary
Marketwire - Thu Feb 13, 7:32AM CST
Navios Maritime Holdings Inc. ("Navios Holdings") (NYSE: NM), announced today that Chairman and CEO Angeliki Frangou, along with members of the Navios Maritime Holdings Inc. management team, will commemorate the Company's 60th Anniversary by ringing the NYSE Closing Bell(R) on Wednesday, February 19, 2014.
Mark Luck Olson Joins Decision Resources Group As Executive Vice President, Global Services
PR Newswire - Wed Feb 12, 9:45AM CST
Decision Resources Group (DRG), one of the world's leading research and advisory firms focusing on healthcare insights, analysis and consulting, announced today that Mark Luck Olson has joined the Company as the Executive Vice President, Global Services. Mr. Olson was most recently an independent strategy consultant with 25 years of experience serving the healthcare industry. At DRG, he will be responsible for bringing together the various professional services brands within DRG (Abacus International, DRG Consulting, Millennium Research Group Consulting, PharmaStrat and Pinsonault Training) to create a cohesive services division that healthcare clients can benefit from holistically. Mr. Olson will report directly to Jim Lang, CEO, DRG.
Idexx Laboratories Up 12.8% Since SmarTrend Uptrend Call (IDXX)
Comtex SmarTrend(R) - Mon Feb 10, 10:03AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 2 month, Idexx Laboratories has returned 12.78% as of today's recent price of $119.98.
Aratana Therapeutics Announces Additions to Board of Directors
PR Newswire - Wed Feb 05, 3:10PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced additions to its Board of Directors. The Board has appointed two new members; Laura Brege, President and Chief Executive Officer of Nodality, Inc., a privately held life sciences company, and Merilee Raines, former Executive Vice President and Chief Financial Officer of companion animal health company IDEXX Laboratories. Mses. Brege and Raines will serve on the Audit Committee of the Board, with Ms. Brege as Chairperson. Aratana also announced the resignation of Board member Ronald Meeusen, Ph.D., Managing Partner of Cultivian Ventures, one of Aratana's early investors.
Idexx Q4 tops, guides '14 low
at Investor's Business Daily - Tue Feb 04, 5:54PM CST
The maker of medical products for pets said Q4 EPS jumped 10.8% to 82 cents, beating views by a penny. Revenue also rose 10.8% to $354.07 mil, topping views for $347.08 mil. Sales at the companion animal group rose 11.4% to $293.6 mil. Idexx...
SmarTrend Watching for Potential Pullback in Shares of Idexx Laboratories After 5.51% Gain
Comtex SmarTrend(R) - Tue Feb 04, 5:26PM CST
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $110.85 to a high of $116.88. Yesterday, the shares gained 5.5%, which took the trading range above the 3-day high of $114.39 on volume of 804,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDEXX Laboratories Announces Fourth Quarter and Full-Year Financial Results
PR Newswire - Tue Feb 04, 6:00AM CST
IDEXX Laboratories, Inc. (NASDAQ: IDXX), today reported that revenues for the fourth quarter of 2013 increased 11% to $354.1 million. Organic revenue growth1 was also 11%. Earnings per diluted share ("EPS") for the quarter ended December 31, 2013 increased 5% to $0.82. Fourth quarter 2012 EPS of $0.78 included a $3.5 million milestone payment earned related to the 2008 sale of product rights previously included in our pharmaceutical product line, which added $0.04 to EPS.
Downgrade Alert for Idexx Laboratories (IDXX)
Comtex SmarTrend(R) - Fri Jan 31, 7:08AM CST
Idexx Laboratories (NASDAQ:IDXX) was downgraded from Hold to Sell at Feltl today. The stock closed yesterday at $113.76 on volume of 433,000 shares, above average daily volume of 393,000. Based on a current price of $113.76, Idexx Laboratories is currently 0.7% above its average consensus analyst price target of $112.92. The stock should find initial support at its 50-day moving average (MA) of $107.26 and further support at its 200-day MA of $98.10.
IDEXX Laboratories to Release 2013 Fourth Quarter and Full-Year Financial Results
PR Newswire - Thu Jan 23, 4:00PM CST
IDEXX Laboratories, Inc. (NASDAQ: IDXX), has scheduled the release of its 2013 fourth quarter and full-year financial results for Tuesday, February 4, at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
New computer buddy volunteers help with IT skills and confidence at Sleaford Library
M2 - Fri Jan 17, 9:14AM CST
People who need help using computers and the internet now have the support of dedicated volunteers at Sleaford Library .
IDACORP, Inc. Declares Dividend
PR Newswire - Thu Jan 16, 3:54PM CST
Directors of IDACORP, Inc. (NYSE:IDA) today declared a common stock dividend of $.43 per share, payable February 28, 2014 to holders of record at the close of business on February 5, 2014.
Idexx Laboratories Shares Up 20.2% Since SmarTrend's Buy Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Mar 12, 11:07AM CDT
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 3 months, Idexx Laboratories has returned 20.18% as of today's recent price of $127.85.
IDEXX Laboratories names Daniel Junius as member of the board
M2 - Wed Mar 12, 7:59AM CDT
Diagnostics and information technology solutions for animal health care company IDEXX Laboratories (NASDAQ:IDXX) announced on Tuesday that Daniel M Junius has been elected as a member of the company's board of directors, with immediate effect.
IDEXX Laboratories Elects Daniel Junius to Board of Directors
PR Newswire - Tue Mar 11, 3:15PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced the unanimous election of Daniel M. Junius as a member of the Company's Board of Directors, effective March 11, 2014. Mr. Junius fills a vacancy on the Board for a Class I director, the remaining term for which ends at the Company's 2015 annual meeting of stockholders.
Idexx Laboratories Has Returned 18.4% Since SmarTrend Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Mar 05, 9:46AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 2 months, Idexx Laboratories has returned 18.42% as of today's recent price of $125.98.
Idexx Laboratories Shares Up 18.4% Since SmarTrend's Buy Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Feb 26, 9:20AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 2 months, Idexx Laboratories has returned 18.44% as of today's recent price of $126.00.
IDEXX Laboratories to Present at Raymond James 35th Annual Institutional Investors Conference
PR Newswire - Tue Feb 25, 3:38PM CST
IDEXX Laboratories, Inc. (NASDAQ: IDXX), announced today that it will participate in the Raymond James 35th Annual Institutional Investors Conference. Brian McKeon, Executive Vice President and Chief Financial Officer, is scheduled to make a presentation on the Company on Tuesday, March 4, 2014 at 11:35 a.m. ET, at the JW Marriott Grande Lakes, Orlando, Florida. Individuals can access the live audio webcast of the presentation through a link on the home page of the IDEXX Laboratories website, www.idexx.com. An archived edition of the presentation will be available for 14 days via the same link.
Insider Trading Alert - IDXX, AGN And BGC Traded By Insiders
at The Street - Tue Feb 25, 9:02AM CST
Stocks with insider trader activity include IDXX, AGN and BGC
Shares of IDXX Up 18.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 18, 4:53PM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.38. In approximately 2 months, Idexx Laboratories has returned 18.06% as of today's recent price of $125.60.
This Company's "Dismal" Performance Masks Excellent Opportunity
John Leonard, The Motley Fool - Motley Fool - Fri Feb 14, 1:30PM CST
Abaxis fell sharply after reporting disappointing results last month. However the recent recovery suggests the market is beginning to realize that the cause for the "dismal" results (the CEO's words) is most likely a one-off occurrence rather...
Navios Maritime Holdings to Ring the NYSE Closing Bell(R), Commemorating the Company's 60th Anniversary
Marketwire - Thu Feb 13, 7:32AM CST
Navios Maritime Holdings Inc. ("Navios Holdings") (NYSE: NM), announced today that Chairman and CEO Angeliki Frangou, along with members of the Navios Maritime Holdings Inc. management team, will commemorate the Company's 60th Anniversary by ringing the NYSE Closing Bell(R) on Wednesday, February 19, 2014.
Mark Luck Olson Joins Decision Resources Group As Executive Vice President, Global Services
PR Newswire - Wed Feb 12, 9:45AM CST
Decision Resources Group (DRG), one of the world's leading research and advisory firms focusing on healthcare insights, analysis and consulting, announced today that Mark Luck Olson has joined the Company as the Executive Vice President, Global Services. Mr. Olson was most recently an independent strategy consultant with 25 years of experience serving the healthcare industry. At DRG, he will be responsible for bringing together the various professional services brands within DRG (Abacus International, DRG Consulting, Millennium Research Group Consulting, PharmaStrat and Pinsonault Training) to create a cohesive services division that healthcare clients can benefit from holistically. Mr. Olson will report directly to Jim Lang, CEO, DRG.
Idexx Laboratories Up 12.8% Since SmarTrend Uptrend Call (IDXX)
Comtex SmarTrend(R) - Mon Feb 10, 10:03AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on December 27th, 2013 at $106.39. In approximately 2 month, Idexx Laboratories has returned 12.78% as of today's recent price of $119.98.
Aratana Therapeutics Announces Additions to Board of Directors
PR Newswire - Wed Feb 05, 3:10PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced additions to its Board of Directors. The Board has appointed two new members; Laura Brege, President and Chief Executive Officer of Nodality, Inc., a privately held life sciences company, and Merilee Raines, former Executive Vice President and Chief Financial Officer of companion animal health company IDEXX Laboratories. Mses. Brege and Raines will serve on the Audit Committee of the Board, with Ms. Brege as Chairperson. Aratana also announced the resignation of Board member Ronald Meeusen, Ph.D., Managing Partner of Cultivian Ventures, one of Aratana's early investors.
Idexx Q4 tops, guides '14 low
at Investor's Business Daily - Tue Feb 04, 5:54PM CST
The maker of medical products for pets said Q4 EPS jumped 10.8% to 82 cents, beating views by a penny. Revenue also rose 10.8% to $354.07 mil, topping views for $347.08 mil. Sales at the companion animal group rose 11.4% to $293.6 mil. Idexx...
SmarTrend Watching for Potential Pullback in Shares of Idexx Laboratories After 5.51% Gain
Comtex SmarTrend(R) - Tue Feb 04, 5:26PM CST
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $110.85 to a high of $116.88. Yesterday, the shares gained 5.5%, which took the trading range above the 3-day high of $114.39 on volume of 804,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDEXX Laboratories Announces Fourth Quarter and Full-Year Financial Results
PR Newswire - Tue Feb 04, 6:00AM CST
IDEXX Laboratories, Inc. (NASDAQ: IDXX), today reported that revenues for the fourth quarter of 2013 increased 11% to $354.1 million. Organic revenue growth1 was also 11%. Earnings per diluted share ("EPS") for the quarter ended December 31, 2013 increased 5% to $0.82. Fourth quarter 2012 EPS of $0.78 included a $3.5 million milestone payment earned related to the 2008 sale of product rights previously included in our pharmaceutical product line, which added $0.04 to EPS.
Downgrade Alert for Idexx Laboratories (IDXX)
Comtex SmarTrend(R) - Fri Jan 31, 7:08AM CST
Idexx Laboratories (NASDAQ:IDXX) was downgraded from Hold to Sell at Feltl today. The stock closed yesterday at $113.76 on volume of 433,000 shares, above average daily volume of 393,000. Based on a current price of $113.76, Idexx Laboratories is currently 0.7% above its average consensus analyst price target of $112.92. The stock should find initial support at its 50-day moving average (MA) of $107.26 and further support at its 200-day MA of $98.10.
IDEXX Laboratories to Release 2013 Fourth Quarter and Full-Year Financial Results
PR Newswire - Thu Jan 23, 4:00PM CST
IDEXX Laboratories, Inc. (NASDAQ: IDXX), has scheduled the release of its 2013 fourth quarter and full-year financial results for Tuesday, February 4, at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
New computer buddy volunteers help with IT skills and confidence at Sleaford Library
M2 - Fri Jan 17, 9:14AM CST
People who need help using computers and the internet now have the support of dedicated volunteers at Sleaford Library .
IDACORP, Inc. Declares Dividend
PR Newswire - Thu Jan 16, 3:54PM CST
Directors of IDACORP, Inc. (NYSE:IDA) today declared a common stock dividend of $.43 per share, payable February 28, 2014 to holders of record at the close of business on February 5, 2014.
(0)
(0)IDEXX Laboratories Inc (IDXX) Stock Research Links
Scroll down for more posts ▼